Onkologie. 2008:2(3):145-149

USE OF ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA - MORE THAN SUCCESSFUL MODEL OF TARGETED TREATMENT IN HEMATOONCOLOGY

Tomáš Szotkowski2, Edgar Faber2, Jan Starý1, Jaromír Hubáček2, Romana Szotkowská2, PhDr. Milena Holzerová2, doc. PhDr. Marie Jarošová CSc2, Karel Indrák2
1 Klinika dětské hematologie a onkologie, UK 2. LF a FN Motol, Praha
2 Hemato-onkologická klinika FN a LF UP v Olomouci

Acute promyelocytic leukemia (APL) belongs to less frequent subtypes of acute myeloid leukemia. However, APL is a very important entity being one of the first malignant diseases treated by targeted therapy and the only one acute myeloid leukemia with a really favorable prognosis. All-trans-retinoic acid (ATRA) caused a real revolution in APL treatment 20 years ago. A vast majority of patients died from intracranial bleeding shortly after diagnosis before the inclusion of ATRA in front-line treatment. Nowadays, it is possible to achieve a long-term remission and perhaps to completely cure 70–80 % of patients.

Keywords: Key words: acute promyelocytic leukemia, all-trans-retinoic acid, targeted treatment.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Szotkowski T, Faber E, Starý J, Hubáček J, Szotkowská R, Holzerová M, et al.. USE OF ALL-TRANS-RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA - MORE THAN SUCCESSFUL MODEL OF TARGETED TREATMENT IN HEMATOONCOLOGY. Onkologie. 2008;2(3):145-149.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957; 159: 189-194. Go to original source... Go to PubMed...
    2. Bernard J, Weil M, Boiron M et al. Acute Promyelocytic Leukemia: Results of Treatment by Daunorubicin. Blood 1973; 41: 489-496. Go to original source...
    3. Rowley JD, Golomb H, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1: 549-550. Go to original source... Go to PubMed...
    4. Breitman TR, Selonick SE, Collins SJ. Induction of diferentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-2940. Go to original source... Go to PubMed...
    5. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572. Go to original source...
    6. Mistry AR, Pedersen EW, Solomon E. The molecular pathogenesis of acute promyelocytic leukemia: implications for the clinical management of the disease. Blood Reviews 2003; 17: 71-97. Go to original source... Go to PubMed...
    7. Catalano A, Dawson MA, Somana K. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007; 110: 4073-4076. Go to original source... Go to PubMed...
    8. Žák P. Akutní promyelocytární leukemie. Postgrad Med 2007; 9: 299-303.
    9. Barbui T, Finazzi G, Falanga A. The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia. Blood 1998; 91: 3093-3102. Go to original source...
    10. Falanga A, Rickles FR. Management of Thrombohemorrhagic Syndromes (THS) in Hematologic Malignancies. Hematology 2007: 165-171. Go to original source... Go to PubMed...
    11. Faber E. Akutní promyelocytární leukemie. v Mayer J, Starý J et al. Leukemie. Praha, Grada Publishing 2002: 266-268.
    12. Sanz M, Martin G, Gonzales M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243. Go to original source... Go to PubMed...
    13. de la Serna J, Montesinos P, Vellenga E et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111: 3395-3402. Go to original source... Go to PubMed...
    14. Lengfelder E, Saussele S, Weisser A et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hemat 2005; 56: 261-274. Go to original source... Go to PubMed...
    15. Beaumont M, Sanz M, Carli PM. Therapy-Related Acute Promyelocytic Leukemia. J Clin Oncol 2003; 21: 2123-2137. Go to original source... Go to PubMed...
    16. Frankel SR, Eardley A, Heller G. All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study. Ann Int Med 1994; 120: 278-286. Go to original source... Go to PubMed...
    17. Sanz MA, Lo Coco F, Martín G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
    18. Avvisatti G, Lo Coco F, Diverio D et al. AIDA (All-trans Retinoic Acid + Idarubicin) in Newly Diagnosed Acute Promyelocytic Leukemia: A Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398. Go to original source...
    19. Sanz MA, Tallman MS, Lo-Coco F. Practise Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia. The Oncologist 2005; 10: 806-814. Go to original source... Go to PubMed...
    20. Cassinat B, Guillemot I, Molucon-Chabrot C et al. Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response. Haematologica 2006; 91: e158-e159.
    21. Culligan DJ, Stevenson D, Chee YL et al. Acute promyelocytic leukemia with t(11; 17) (q23; q12-21) and a good response to prolonged ATRA and combination chemotherapy. Br J Haematol 1998; 100: 328-330. Go to original source... Go to PubMed...
    22. Cetkovský P. Komplikace spojené s výskytem a terapií akutní promyelocytární leukemie. In Cetkovský P et al. Intenzívní péče v hematologii. Praha, Galén 2004: 463-467.
    23. Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther 2008; 33: 331-338. Go to original source... Go to PubMed...
    24. Lo Coco F, Cimino G, Breccia M et al. Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999. Go to original source... Go to PubMed...
    25. Sanz M, Fenaux P, Lo Coco F. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 2005; 90: 1231-1235. Go to PubMed...
    26. De Botton S, Coiteux V, Chevret S et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004; 22: 1404-1412. Go to original source... Go to PubMed...
    27. Ortega J, Madero L, Martín G et al. Treatment with all-trans-retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA group. J Clin Oncol 2005; 23: 7632-7640. Go to original source... Go to PubMed...
    28. Testi AM, Biondi A, Lo Coco F et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453. Go to original source... Go to PubMed...
    29. Mann G, Reinhardt D, Ritter J et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematom 2001; 80: 417-422. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.